Mutations in the LDL receptor (LDLR) cause familial hypercholesterolaemia (FH) in an autosomal dominant manner. The condition frequently progresses to coronary atherosclerosis. We describe a patient with FH, but without ischaemic heart disease, who had a novel frameshift mutation (327insC) in exon 4 of the LDLR gene. This mutation introduced a premature termination codon (TGA, codon 158). The patient was a 59-year-old man who had presented with hypercholesterolaemia and a plasma total cholesterol (TC) concentration of 12 ¢ 2 mmol/L at age 44 years. The mutation 327insC in this patient was heterozygous and hypercholesterolaemia was common within his family. Despite taking lipid-lowering medications (probucol and pravastatin) for more than 20 years, his TC concentration hardly fell below 7 ¢ 8 mmol/L. However, neither the patient nor anyone else in his family developed characteristic symptoms of ischaemic heart disease or xanthoma. This patient was discovered by an intensive mutation survey among 22 unrelated Japanese with FH mainly in the Kanto area of Japan, suggesting a low incidence of the mutation in the area.
Introduction
Familial hypercholesterolaemia (FH) is an autosomal dominant disease that is characterized by elevated levels of LDL-cholesterol, xanthoma and premature atherosclerosis. 1 The LDL receptor (LDLR) is a cellsurface protein that mediates the speci¢c binding, uptake and degradation of plasma LDL, and functional damage to this receptor impairs the catabolism of plasma LDL and elevates plasma LDL concentrations. 2 Various mutations in the gene for LDLR have been reported, including deletions, insertions, missense and nonsense types. 3, 4 The determination of dominant but infrequent mutations in Japanese FH should lead to e¤cient diagnostic procedures. However, much of the genetics remains unknown. One survey found ¢ve mutations, including four that are common, in 31¢5% (39 out of 124) of Japanese patients with FH. 4 Heteroduplex analysis detected mismatches between doublestranded DNA, consisting of a wild-type strand and a complementary strand with an altered nucleotide sequence. 5 We used this technique to search for mutations in all 18 exon sequences of the LDLR gene, and found a novel mutation heterozygous for an insertion of C in exon 4 (327insC). The patient had long-term hypercholesterolaemia, and the condition was prevalent among his family members. However, the patient and his family were free from ischaemic heart disease. The frequency of the mutation was investigated and its relationship to an atheroprotective e¡ect related or unrelated to the unique LDLR mutation of the patient is discussed.
Case report
A 59-year-old Japanese man (patient HW) has been undergoing follow-up for control of plasma cholesterol levels. A high plasma cholesterol concentration (lipid pro¢le not recorded) was initially noted when the patient was 22 years of age. Medication to lower plasma lipid was prescribed 3 years later by a physician at another facility (medical records not available). The patient visited Kyorin University Hospital at the age 44 years. A physical examination at that time showed a normal bulbar conjunctiva and skin and no Achilles tendon thickening (rˆ2¢2 cm, lˆ2 ¢1 cm; as well as skin and soft tissue by direct measurement, rˆlˆ0 ¢5 cm by X-ray study). His body mass index was 23¢6 (body weight 59 kg, height 158 cm) and blood pressure 13¢3/10¢1kPa (100/76 mmHg). He consumed one glass (250 mL) of beer every day, but did not smoke. An examination of lipid pro¢les within his immediate family found that his brothers, but not his daughter, had high plasma total cholesterol (TC) concentrations. Other relatives (three uncles, one niece and one nephew) also had high plasma TC concentrations (see Fig. 1a ). None of his relatives had ischaemic heart disease, diabetes mellitus, hypertension or xanthoma. Laboratory ¢ndings at age 44 years during his initial visit disclosed increases in TC (12¢2 mmol/ L) and triglycerides (1¢9 mmol/ L). The concentration of HDL-cholesterol was 1¢1mmol/ L. Despite taking probucol and pravastatin for more than 20 years, his TC concentration almost always remained above 7¢8 mmol/ L (see Fig. 1b ). However, he had no characteristic symptoms of ischaemic heart disease and electrocardiograms were normal (both at rest and during exercise).
Polymerase chain reaction-heteroduplex analysis, DNA sequencing of exon 4 and other assay
The patient gave his written informed consent to participate in all procedures associated with the study.
The LDLR gene of the patient was ampli¢ed from 1 mg of genomic DNA obtained from peripheral blood leucocytes by polymerase chain reaction (PCR). Exons 1^18 of the LDLR gene were ampli¢ed using the described pairs of primers. 6 Heteroduplex analysis of exon 4 from the patient showed an additional band compared with a control (see Fig. 2a ), indicating that the mutation was heterozygous. Subsequent DNA sequencing of the mutant heteroduplex band revealed a single base insertion C at codon 109 that shifted the reading frame and introduced a premature termination codon (TGA, codon 158) in the LDLR gene (327insC; see Fig. 2b ). The heteroduplex bands of the other 17 exons of the gene were similar to that from a control, and the patient was negative for the 1845+2T!C mutation 4 (data not shown). Lymphocyte LDLR activity, as estimated by £ow cytometric assay, 7 of the patient at 64 years of age was 76% (normal reference is over 80%) and the activity was shown to be reduced.
Discussion
The novel frame-shift mutation 327insC would result in the absence of a membrane -spanning region of the protein that would cause the secretion of truncated LDLR into the extracellular space. The LDLR activity would be considerably decreased by the 327insC mutation, which would explain the hypercholesterolaemia. However, we detected the mutation only in the proband and his family did not consent to a genetic survey. Thus the actual relationship between the mutation and hypercholesterolaemia is unclear. The unique and important aspect of this patient is that he has remained free of ischaemic heart disease in the presence of long-term hypercholesterolaemia. Although the hypercholesterolaemia was sensitive to medication and TC was reduced by over 20%, his TC concentration never reached less than 7¢8 mmol/ L. The patient is currently alive at age 65 years with a TC concentration greater than 7 ¢ 8 mmol/ L (thus, he has been con¢rmed as hypercholesterolaemic for 21 years), yet he has not developed ischaemic heart disease. Male heterozygous FH is assumed to develop into detectable coronary artery stenosis after 17 years of age, 8 and the plasma cholesterol levels of this patient were high enough to be associated with coronary atherosclerosis. Normal HDL-cholesterol levels that facilitate cellular cholesterol e¥ux from the peripheral tissues to the liver, a traditional Japanese low-fat diet and moderate alcohol consumption have probably exerted a favourable e¡ect, and the absence of other risk factors for ischaemic heart disease such as obesity, diabetes mellitus and smoking may also have protected the patient from atherosclerosis. Mechanisms of atherosclerosis development other than hyperlipidaemia have recently been proposed. For example, oxidatively modi¢ed LDL is thought to play an important role in the development of atherosclerosis through the accumulation of esteri¢ed cholesterol in the cells of vessel walls. 9 Recently, we found that the serum malondialdehyde -modi¢ed LDL (MDA-LDL) concentration of the patient was increased (187¢9 U/L; reference range 76¢7^40¢9). The connection of the increased serum MDA-LDL level with the absence of ischaemic heart disease in the patient is unclear. However, the observation is consistent with the idea that local tissue oxidized LDL rather than plasma oxidized LDL has a critical role in the development of atherosclerosis.
Information about dominant but infrequent mutations in Japanese FH could simplify diagnosis. To understand more about the genetics of LDLR in Japanese FH, 18 exons and an intron in the LDLR gene from 22 unrelated Japanese with FH were surveyed using the heteroduplex procedure and PCR^restriction fragment length polymorphism (RFLP). Among these 22 patients from the Kanto area (central region) of Japan, we found two with the 1845+2T!C mutation, 4 two with a D412H mutation and one with a K790X mutation. 10 The incidence of mutation in the present study (10% of 1845+2T!C mutation and 5% of K790X) was consistent with the reported incidence of 13¢3% (16/120) of the former and 6¢6% (8/120) of the latter. 4 However, the D412H incidence of 10% in the present study was higher than that reported, indicating that the mutation was not detected in 76 Japanese with FH, 10 probably due to a founder proband (arrow) is heterozygous for the mutation. Age at lipid analysis and lipid pro les of each patient are shown. The family members suspected of being heterozygous for the mutation (high plasma total cholesterol) are indicated by closed symbols. Open symbols indicate individuals suspected to be free of the mutation (with lipid pro le), or who have not been examined (no lipid pro le). *Individuals whose plasma total cholesterol levels were known to be high, but who were not examined here. TCˆtotal cholesterol; TGˆtriglycerides; HDL-CˆHDL-cholesterol. Family members of the proband refused to comply with a genetic survey. (b) Time course lipid pro le of patient HW. TG increased temporarily at 52 years of age due to unknown causes.
e¡ect^i.e. the di¡erence in mutation frequency between populations. The incidence of the K790X mutation is relatively high in the Hokuriku area, but not in other areas of Japan. 11 The 0¢45% (1/22) frequency of 327insC among our FH patients suggested that the incidence of the mutation would be relatively low compared with that of the other LDLR mutations that cause FH in the Kanto area. However, because populations have moved into the Kanto area over the past 100 years and because founder e¡ects cannot be completely ruled out, the mutation might be common in some other area of Japan.
Detecting a rare mutation solely by the heteroduplex method may not be totally satisfactory. The positive yield (combined with PCR^RFLP for the mutation 1845+2T!C) was only 22¢7% (5 out of 22 patients) among the unrelated FH, which was well below the reported 31¢5% (39 out of 124) frequency of the common LDLR mutations in unrelated Japanese with FH. 4 This implies that di¡erent mutations remain undetected in the other patients, or that mutations in other genes produce the same clinical manifestations and that such patients do not have a gene mutation for classical FH. The mutation of LDLR would not always be linked to hypercholesterolaemia as well as to ischaemic heart disease. Thus, further e¡orts to identify common and clinically signi¢cant LDLR mutations (if possible by a more sensitive method than that reported here) and to establish a comprehensive strategy with which to classify Japanese FH are required to understand the genetics associated with this condition. 
